A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer

Figure 3

Restaging CT post 15 cycles of Nivolumab. Image on the top shows some reduction in RLL mass and the image on the bottom shows that the LLL mass had increased significantly.